33results about How to "Meet the pharmaceutical requirements for production, transportation and storage" patented technology

The invention relates to a crystal form of a renal outer medullary potassium channel inhibitor and a preparation method of the crystal form. Specifically, the invention relates to an IV crystal form of an L-tartrate of a renal outer medullary potassium channel (ROMK) inhibitor and a preparation method of the IV crystal form. The IV crystal form has good chemical stability and crystal form stability, a used crystallization solvent is low in toxicity and residue, and the IV crystal form can be better used for clinical treatment.

The present invention relates to an I-type crystal of L-alanine-(14-oridonin) ester trifluoroacetate and a preparation method therefor.The preparation method comprises crystallizing a L-alanine-(14-oridonin) ester trifluoroacetate solid in any crystal form or amorphous form in a single organic solvent or a mixed organic solvent thereof to obtain the I-type crystal of the L-alanine-(14-oridonin) ester trifluoroacetate.The I-type crystal of the L-alanine-(14-oridonin) ester trifluoroacetate obtained in the present invention has a good crystal form stability and chemical stability, and uses a crystallization solvent which has a low toxicity and low residue, and can be better used in clinical treatments.

The invention relates to a crystal form of a cyclin dependent protein kinase inhibitor and a preparation method thereof. Specifically, the invention relates to a type I crystal of a cyclin dependent protein kinase (CDK4&6) inhibitor and a preparation method thereof. Specifically, the invention relates to a type I crystal of 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperidine-4-yl)pyridine-2-yl)amino)pyridine[2, 3-d]pyrimidine-7(8H)-one (formula (I) compound) and a preparation method thereof, wherein the crystal has an X-ray powder diffraction spectrum shown as Figure 1. The type I crystal of the formula (I) compound obtained by the invention has good chemical stability and crystal form stability, and the used crystal solvent has low toxicity and low residue, thus being better applicable to clinical treatment. (formula (I)).

The invention relates to a crystal form of an intestinal type 2B sodium phosphate cotransporter (Npt2b) inhibitor and a preparation method thereof. Specifically, the present invention relates to N 1 ‑Methyl‑N 1 ‑(2‑morpholinoethyl)‑N 3 ‑(3‑(4‑phenethylphenylcarbamoyl)‑4,5,6,7‑tetrahydrobenzo[b]thiophen‑2‑yl)isophthalamide sulfate (formula (I) Compound) II crystal form and preparation method. The crystal form II of the compound of formula (I) obtained in the present invention has good chemical stability and crystal form stability, and can be better used in clinical treatment.

The present invention relates to a B crystal form of ertacarline hydrochloride and a preparation method thereof. The B crystal form of ertacarline hydrochloride obtained in the present invention has good crystal form stability and chemical stability, and has good bioavailability , can be better used in clinical treatment.

The invention relates to a crystal form of a free alkali of an imidazoisoindole derivative and a preparation method thereof. Specifically, the invention relates to the crystal form II of a compound asshown in a formula (I) which is described in the specification, and the chemical name of the crystal form II is (S)-2-(4-(4-(4-(6-fluoro-5H-imidazo[5,1-a]isoindol-5-yl)piperidin-1-yl)phenyl)-1H-pyrazol-1-yl)ethanol. The invention further relates to the preparation method of the crystal form II, the application of the crystal form II to a pharmaceutical composition, and the application of the crystal form II and the composition to the treatment of diseases having pathological features of an IDO-mediated (indoleamine-pyrrole-2,3-dioxygenase-mediated) tryptophan metabolism approach. The preparedcrystal form II of the compound as shown in the formula (I) has good stability and can be better used for clinical treatment.

The invention relates to a pharmaceutically acceptable salt, crystal form and preparation method of pyrazolo heteroaryl derivatives. The new pharmaceutically acceptable salt and the new crystal form of the present invention have good stability and can be better used in clinical treatment.

The invention relates to a crystal form and a preparation method of pyrazolo heteroaryl derivatives. In particular, the present invention relates to A of 6-butoxy-1-(4-(pyrrolidin-1-ylmethyl)benzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Crystal form, B crystal form, C crystal form, D crystal form, E crystal form, F crystal form, G crystal form, H crystal form and preparation methods thereof. The crystal form of the compound of formula (I) of the present invention has good crystal form stability, and can be better used in clinical treatment,

The invention relates to a free base crystal form of phenylpropanamide derivatives and a preparation method thereof. Specifically, the present invention relates to a new crystal form of the free base of phenylpropanamide derivatives, that is, crystal form I of the compound represented by formula (I). The present invention also relates to the preparation method of the I crystal form, the pharmaceutical composition and its use in the preparation of medicines for preventing and / or treating related diseases mediated by KOR agonists. The crystal form I of the compound of formula (I) obtained in the present invention has good stability and can be better used in clinical treatment.

The invention relates to a crystallization form of malate of a tyrosine kinase inhibitor, and a preparation method thereof, and concretely relates to an II type crystal of L-malate of 5-(2-diethylamino-ethyl)-2-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidene-methyl)-3-methyl-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one (a compound of formula (I)), and a preparation method thereof. The II type crystal of the compound (I) obtained in the invention has the advantages of good crystal form stability and chemical stability, and a crystallization solvent used in the invention has low toxicity and low residual, so the II type crystal of the compound (I) can be well used in clinic treatment.